DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes: Early assessment of cardiovascular safety in a nationwide setting

U. M. Mogensen, C. Andersson, E. L. Fosbol, T. K. Schramm, A. Vaag, N. M. Scheller, Christian Torp-Pedersen, G. Gislason, L. Kober

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number5929
JournalEuropean Heart Journal
Volume34
Issue number1. Supplement
Pages (from-to)1111
ISSN0195-668X
DOIs
Publication statusPublished - 2013
EventCongress of the European Society of Cardiology, ESC - Amsterdam, Netherlands
Duration: 31 Aug 20134 Sep 2013

Conference

ConferenceCongress of the European Society of Cardiology, ESC
CountryNetherlands
CityAmsterdam
Period31/08/201304/09/2013

Cite this

Mogensen, U. M., Andersson, C., Fosbol, E. L., Schramm, T. K., Vaag, A., Scheller, N. M., Torp-Pedersen, C., Gislason, G., & Kober, L. (2013). DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes: Early assessment of cardiovascular safety in a nationwide setting. European Heart Journal, 34(1. Supplement), 1111. [5929]. https://doi.org/10.1093/eurheartj/eht311.5929